While silicon incorporation is a compelling strategy in drug discovery due to its bioisosteric properties and the chiral 1-aminotetralin is a privileged scaffold, the synthesis of enantiopure silicon-bridged 1-aminotetralin analogues poses significant challenges and has thus far hampered their medicinal exploration. Herein, we present the strategy for the enantioselective synthesis of 1-amino-3-silatetralins via a palladium-catalyzed asymmetric 4 + 2 annulation of benzosilacyclobutenes with N-allenamides by employing a chiral phosphoramidite ligand. Notably, this protocol leverages the dual role of N-allenamides as both a two-carbon synthon and a nitrogen donor, enabling efficient assembly of structurally diverse chiral 1-amino-3-silatetralins in good yields and high enantioselectivity with broad functional group tolerance. The reaction proceeds with exclusive proximal C═C bond insertion of N-allenamides and selective Si−C(sp2) bond cleavage of benzosilacyclobutenes, a regioselectivity well supported by DFT calculations. This methodology thereby provides access to inaccessible three-dimensional architectures, facilitating drug discovery efforts focused on silicon-based bioisosteres.
Building similarity graph...
Analyzing shared references across papers
Loading...
Yu Sun
Rundong Lu
Hang Zhou
ACS Catalysis
Fudan University
Yangzhou University
Building similarity graph...
Analyzing shared references across papers
Loading...
Sun et al. (Tue,) studied this question.
www.synapsesocial.com/papers/69e1cdc45cdc762e9d85715b — DOI: https://doi.org/10.1021/acscatal.5c08823